Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeted spatial transcriptomic profiling of pleural mesothelioma using 10x Genomics Xenium

ABSTRACT: Targeted spatial transcriptomic profiling was performed on seven formalin-fixed paraffin-embedded pleural mesothelioma tumor samples from four cases using the 10x Genomics Xenium platform. The Xenium Human Immuno-Oncology panel supplemented with 100 additional custom genes selected from known pleural mesothelioma biomarkers and single-cell RNA-seq-derived marker genes was used. Raw and processed Xenium files are provided for each sample. To ensure data integrity with downloaded Xenium files, md5 checksums are provided in 'Xenium_GEO.md5'. This dataset is part of a multi-modality study including matched scRNA-seq, bulk RNA-seq, and Xenium spatial transcriptomics generated from overlapping pleural mesothelioma samples. Related controlled-access sequencing data are available in dbGaP under accession phs004285.

ORGANISM(S): Homo sapiens

PROVIDER: GSE327347 | GEO | 2026/04/08

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Bulk RNA-seq profiling of pleural mesothelioma and comparator pleural specimens

Project description:This GEO submission contains processed bulk RNA sequencing data generated from pleural mesothelioma tumors and comparator pleural specimens. Raw sequencing data are available through controlled access in dbGaP under accession phs004285. Processed gene expression matrices and sample-level metadata for the bulk RNA-seq libraries are provided in this submission.

2026-04-07 | GSE327166 | GEO

Single-cell RNA-seq profiling of pleural mesothelioma and comparator pleural specimens

Project description:This GEO submission contains processed single-cell RNA sequencing data generated using the Seq-Well platform from pleural mesothelioma tumors and comparator pleural specimens. Raw sequencing data are available through controlled access in dbGaP under accession phs004285. Processed expression matrices and cell-level metadata for the single-cell libraries are provided in this submission.

2026-04-07 | GSE327167 | GEO

Targeted spatial transcriptomic profiling of pleural mesothelioma using 10x Genomics Xenium

Project description:Targeted spatial transcriptomic profiling of pleural mesothelioma using 10x Genomics Xenium

| PRJNA1450567 | ENA

Human pleural effusion LC-MSMS

Project description:We screened pleural effusion proteomes of mesothelioma and lung adenocarcinoma patients to identify novel soluble mesothelioma biomarkers. We performed quantitative mass spectrometry-(MS-) based proteomics using isobaric tags for relative and absolute quantification (iTRAQ) and used narrow range immobilized pH gradient/high resolution isoelectric focusing (IPG/HiRIEF; pH 4 to 4.25) prior to analysis by nano liquid chromatography-coupled MS/MS. Pleural effusions from patients with malignant mesothelioma (n=6), lung adenocarcinoma (n=6), or benign mesotheliosis (n=7) were analyzed, and more than 1,300 proteins were identified.

2014-01-14 | PXD000531 | Pride

GeoMX spatial transcriptomic on biphasic Malignant Pleural Mesothelioma

Project description:GeoMX spatial transcriptomic on biphasic Malignant Pleural Mesothelioma

| PRJEB62875 | ENA

Comparison of imaging based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed paraffin-embedded tumor samples [Xenium]

Project description:Imaging-based spatial transcriptomics (ST) is evolving as a pivotal technology in studying tumor biology and associated microenvironments. However, the strengths of the commercially available ST platforms in studying spatial biology have not been systematically evaluated using rigorously controlled experiments. We use serial 5 m sections of formalin-fixed, paraffin-embedded surgically resected lung adenocarcinoma and pleural mesothelioma samples in tissue microarrays to compare the performance of the ST platforms (CosMx, MERFISH, and Xenium (uni/multi-modal)) in reference to bulk RNA sequencing, multiplex immunofluorescence, GeoMx, and hematoxylin and eosin staining data. In addition to an objective assessment of automatic cell segmentation and phenotyping, we perform a manual phenotyping evaluation to assess pathologically meaningful comparisons between ST platforms. Here, we show the intricate differences between the ST platforms, reveal the importance of parameters such probe design in determining the data quality, and suggest reliable workflows for accurate spatial profiling and molecular discovery.

2025-06-30 | GSE300007 | GEO

Identification of novel markers for malignant pleural mesothelioma diagnosis

Project description:Diagnosis of malignant pleural mesothelioma (MPM) is difficult, the most common differential diagnosis being benign pleural diseases and metastatic adenocarcinomas. In order to identify novel markers able to improve diagnostic accuracy, we performed a genome-wide gene expression analysis on tumor cells lines established from pleural effusions (13 MPM and 4 lung adenocarcinoma). Our microarray analysis led to the identification of genes encoding novel cellular and soluble markers whose expression was validated by RT-qPCR. Immunohistochemical staining of tumor biopsies with anti-type-III collagen antibodies were positive in mesothelioma cells but not in adenocarcinoma cells. Using ELISA, we showed that the C-C motif chemokine 2 (CCL2) concentration was significantly higher in pleural effusions from patients with mesothelioma (n = 61) than in subjects with adenocarcinoma (n = 25) or with benign pleural effusions (n = 15): median (interquartile range) = 2.99 ng/mL (1.76-6.01) versus 0.99 ng/mL (0.51-1.83) and 1.47 ng/mL (0.80-1.56), respectively, P < 0.0001. Conversely, the galectin-3 concentration was lower in mesothelioma: 11.50 ng/mL (6.73-23.53) versus 24.74 ng/mL (20.42-70.35) and 17.64 ng/mL (14.81-24.68), respectively, P < 0.0001. The AUC for CCL2 were 0.8030 and 0.7716 for differentiating mesothelioma from adenocarcinoma or benign effusions, respectively. Similarly, the AUC obtained for galectin-3 were 0.7980 and 0.6923, respectively. In conclusion, type-III collagen, CCL2 and galectin-3 are promising new diagnostic markers for mesothelioma.

2009-07-25 | GSE17310 | GEO

Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions

Project description:RATIONALE: Using BG00001 to insert the gene for interferon-beta into a person’s pleural cavity may improve the body’s ability to fight cancer. PURPOSE: Phase I trial to study the effectiveness of intrapleural BG00001 in treating patients who have malignant pleural mesothelioma or malignant pleural effusions.

| 2009653 | ecrin-mdr-crc

CDKN2A deletion remodels immune infiltrate in Diffuse Pleural Mesothelioma

Project description:RNA extracted from diagnostic tumor samples of 82 patients affected by Diffuse Pleural Mesothelioma was analyzed on the nCounter system using the PanCancer Immune Profiling Panel.

2025-09-03 | GSE302048 | GEO

Transcription profiling of human pleural mesothelioma versus parietal and visceral pleura

Project description:Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura

2009-01-01 | E-MTAB-47 | biostudies-arrayexpress